

EQA round: BM2/24 - Bone Markers

Deadline: 25.10.2024

Setup: groups - R (manufacturer of kit); Slovakia; minimal size of the groups n = 5

RoM = robust average	AV = assigned value	D _{max} = acceptable difference
SD = standard deviation	CVPG = consensus of the participants' groups	LL = lower limit
CV = coefficient of variation	U _{AV} = expanded uncertainty of the assigned value (k = 2)	UL = upper limit
N _{tot} = total number of the results		N _{eva} = number of the results assessed
N _{out} = number of the results removed before calculation		N _{suc} = number of successful results
		S _{rel} = relative success

Test Sample Group	[unit]	RoM	SD	CV [%]	N _{tot}	N _{out}	Comparability					N _{eva}	N _{suc}	S _{rel} [%]
							AV	U _{AV}	D _{max}	LL	UL			
(435) 25-hydroxyvitamin D	[nmol/L]				27							26	25	96
Sample A		57,8	10	18	27							26	26	100
(1) Abbott		49,9	2,8	5,6	7	0	CVPG	50,5	0,91	33%	33,8	67,2	7	
(60) Roche		59,4	7,8	13	15	0	CVPG	59,6	1,8	33%	39,9	79,3	15	
Other					5	0							4	
							3x 12, 1x 179, 1x 998							
Sample B		115	14	12	27							26	25	96
(1) Abbott		108	3,9	3,6	7	0	CVPG	108	1,6	33%	72,3	144	7	
(60) Roche		114	13	12	15	0	CVPG	113	2,7	33%	75,7	151	15	
Other					5	0							4	
							3x 12, 1x 179, 1x 998							
(434) Osteocalcin	[µg/L]				18							16	16	100
Sample A		19,8	0,89	4,5	18							16	16	100
(60) Roche		19,9	0,74	3,7	16	0	CVPG	20	0,22	13%	17,4	22,6	16	
Other					2	0							0	
							1x 73, 1x 164							
Sample B		85,6	4,8	5,6	18							16	16	100
(60) Roche		85,5	3,9	4,6	16	0	CVPG	87,5	1,6	13%	76,1	98,9	16	
Other					2	0							0	
							1x 73, 1x 164							
(433) P1NP	[µg/L]				14							14	13	93
Sample A		28,5	1	3,7	14							14	13	93
(60) Roche		28,4	0,93	3,3	13	0	CVPG	28,1	0,44	20%	22,4	33,8	13	
Other					1	0							1	
							1x 73							
Sample B		187	11	6,2	14							14	14	100
(60) Roche		185	10	5,4	13	0	CVPG	185	2,8	20%	148	222	13	
Other					1	0							1	
							1x 73							
(436) Parathyrin biointact (PTH 1-84)	[pmol/L]				1							1	1	100
Sample A		4,09			1							1	1	100
Other					1	0						1		
							1x 164							
Sample B		15,8			1							1	1	100
Other					1	0						1		
							1x 164							
(431) Parathyrin intact (PTH)	[pmol/L]				25							23	22	96
Sample A		6,61	2,1	32	25							23	22	96
(60) Roche		5,79	0,56	9,6	13	0	CVPG	5,78	0,22	23%	4,45	7,11	13	
Other					12	1							10	
							4x 1, 3x 12, 1x 29, 1x 58, 3x 179							
Sample B		22	7,3	33	25							23	22	96
(60) Roche		19,8	1,7	8,5	13	0	CVPG	20	0,57	23%	15,4	24,6	13	
Other					12	0							10	
							4x 1, 3x 12, 1x 29, 1x 58, 3x 179							
(432) Collagen telopeptide CTx-β	[ng/L]				20							20	20	100
Sample A		307	24	7,9	20							20	20	100
(60) Roche		309	22	7,2	19	0	CVPG	314	5,9	17%	260	368	19	
Other					1	0							1	
							1x 73							
Sample B		655	57	8,7	20							20	20	100
(60) Roche		660	53	8,1	19	0	CVPG	680	20	17%	564	796	19	
Other					1	0							1	
							1x 73							